Method for manufacturing microneedle

The micromolding technique with a methanol and water washing process optimizes the cleaning of microneedles, addressing inefficiencies and safety concerns by effectively removing impurities, ensuring the microneedles are safe for use in living organisms and improving manufacturing efficiency.

WO2024242163A1PCT designated stage expired Publication Date: 2024-11-28KANAGAWA INST OF IND SCI & TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018957
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-24
Filing Date
2024-05-23
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing methods for manufacturing microneedles are inefficient in removing unreacted monomers and unpolymerized polymers, known as impurities, which can be harmful when applied to living organisms, and require lengthy washing periods to ensure safety and productivity.

Method used

A method involving a micromolding technique using a mold with a pregel solution containing a monomer mixture, followed by polymerization to form a gel composition, and subsequent washing with a mixed solution of methanol and water to optimize cleaning, ensuring safety and efficiency by immersing the molded body in the cleaning solution until the pH reaches 6.4 or higher.

Benefits of technology

This approach effectively removes impurities from microneedles, ensuring their safety for use in living organisms and improving productivity by optimizing the cleaning process, thereby enhancing the manufacturing efficiency of microneedles.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018957_28112024_PF_FP_ABST
    Figure JP2024018957_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to optimize washing of a microneedle taken out from a mold while securing safety in a living body. This method for manufacturing a microneedle comprises: a step for preparing a mold in which a cavity corresponding to the structure of a microneedle is formed; a step for preparing a pre-gel solution containing a monomer mixture; a step for injecting a pre-gel solution into a prescribed part of the mold; a step for polymerizing the monomer mixture in the pre-gel solution in the mold to form a gel composition; a step for taking out the obtained molded body from the mold; a step for washing the molded body taken out from the mold; and a step for drying the molded body after washing. The step for washing the molded body includes immersing the molded body in a mixed solution of methanol and water.
Need to check novelty before this filing date? Find Prior Art

Description

Microneedle manufacturing method

[0001] The present invention relates to a method for manufacturing a microneedle.

[0002] Microneedles are known as devices for transdermally administering drugs. As disclosed in Patent Document 1, for example, microneedles are provided as patches in which multiple needles, each 1 mm long and carrying the drug to be administered, are arranged in an array on a flat base. The microneedles are configured to deliver the drug via the needles when applied to the skin surface. Therefore, microneedles have the advantage of being able to administer drugs continuously over a long period of time in a minimally invasive manner.

[0003] Patent Document 1 also discloses a micromolding technique using a mold as a method for manufacturing microneedles. The method includes the steps of preparing a mold in which a base portion and a cavity corresponding to the needle are formed, injecting a pre-gel solution containing a monomer mixture into the cavity portion of the mold corresponding to the needle, polymerizing the monomer mixture in the pre-gel solution to form a gel composition, forming a base portion integrally with the gel composition within the mold containing the gel composition, and removing the resulting molded product, the microneedle, from the mold.

[0004] The microneedles disclosed in Patent Document 1 are primarily intended for the delivery of insulin, among other drugs, for the treatment of diabetes, and the monomer mixture contains a phenylboronic acid (PBA)-based monomer capable of reversibly binding to glucose. By incorporating insulin into a gel composition obtained by polymerization of the monomer mixture, the release of insulin from the gel composition can be controlled according to the glucose concentration.

[0005] Here, even if the gel composition, such as the monomer concentration and crosslink density, is optimized in the process of forming the gel composition, polymerization does not occur with a 100% probability. Therefore, unreacted monomers and unpolymerized polymers (these monomers and unpolymerized polymers are collectively referred to as "impurities" in this specification) are present in the microneedles removed from the mold. Therefore, to remove these impurities, the microneedles are washed after being removed from the mold. A cleaning solution that is a mixed solution of methanol and water is used as the cleaning solution for washing the microneedles. Because the boronic acid monomers in the gel composition are eluted into the mixed solution by washing, a washing period of 5 to 7 days is set using the pH of the cleaning solution as an indicator, for example, until the pH reaches 6.4 or higher.

[0006] Patent Document 1: International Publication No. 2019 / 182099

[0007] As mentioned above, the pH of the cleaning solution has conventionally been used as an indicator of cleaning effectiveness. However, since microneedles are directly applied to living organisms, it is important that safety in living organisms is ensured. In addition, in order to improve the productivity of microneedles, it is also important to perform cleaning efficiently. Therefore, one of the objects of the present invention is to optimize the cleaning of microneedles removed from a mold while ensuring safety in living organisms.

[0008] According to one aspect of the present invention, there is provided a method for manufacturing a microneedle, the method comprising the steps of: preparing a mold having a base portion and at least one needle portion integrally formed on the base portion, the mold having a cavity formed therein corresponding to the base portion and the needle portion of the microneedle; preparing a pre-gel solution containing a monomer mixture; injecting the pre-gel solution into at least the cavity portion of the mold corresponding to the needle; polymerizing the monomer mixture in the pre-gel solution in the mold to form a gel composition; removing the obtained molded body from the mold; washing the molded body removed from the mold; and drying the molded body after washing, wherein the step of washing the molded body comprises immersing the molded body in a mixed solution of methanol and water.

[0009] According to one aspect of the present invention, cleaning of microneedles after removal from a mold can be optimized while ensuring safety in living organisms.

[0010] Fig. 2 is a side view of a microneedle according to one embodiment of the present invention. Fig. 3 is a cross-sectional view of one form of a microneedle having a reservoir. Fig. 4 is a cross-sectional view of one form of a mold used in manufacturing the microneedle shown in Fig. 1. Fig. 5 is a graph showing the cleaning effect of a molded body in an example.

[0011] <Microneedles> First, the microneedles will be described. Referring to FIG. 1 , a microneedle 10 according to one embodiment of the present invention is shown, which has a base portion 100 and a plurality of needles 110 and is provided as a patch to be attached to the skin. The base portion 100 is a sheet-like portion that supports the plurality of needles 110. The plurality of needles 110 are supported by the base portion 100, and are configured as a needle array. The needles 110 are portions that puncture the skin when the microneedle 10 is in use, and have sharp tips. The base portion 100 and the needles 110 may be made of different materials or may be made of the same material. When the base portion 100 and the needles 110 are made of the same material, they can be manufactured simultaneously. At least the needles 110 are hydrophilic, and before use, the microneedles 10 carry a drug therein by permeating the drug. The needle 110 has a high mechanical strength sufficient to puncture the skin before puncturing it, and has the property of absorbing water and releasing a drug immediately after puncturing the skin. In this specification, the microneedle is also referred to as a "drug delivery microneedle."

[0012] [Base Portion] The base portion 100 can be made of various materials as long as it has the necessary mechanical strength to allow the needles 110 to puncture the skin well against the elastic force of the skin when puncturing the multiple needles 110. Examples of such materials include polymer materials, porous ceramic materials, and metal materials. Furthermore, the base portion 100 is preferably made of a biocompatible material. In one aspect, the base portion is preferably flexible enough to deform along the skin.

[0013] The base 100 can have a reservoir for a drug to be released from the needle 110. By having a reservoir, the drug can be released over an extended period of time (e.g., seven days). A microneedle capable of releasing a drug over an extended period of time can be suitably used as an insulin delivery microneedle that administers insulin as a drug in response to blood glucose levels.

[0014] The reservoir can be formed, for example, by forming the base portion 100 into a concave (cup-shaped) shape with an open top. Alternatively, the base portion 100 can be formed from the same material as the needles 110, and the base portion 100 itself, which is permeated with a drug, can serve as the reservoir. In this case, the base portion 100 and the multiple needles 110 can be formed simultaneously by integral molding. In either case, the base portion 100 is preferably made of a material that does not impede the continuity of drug flow from the needles 110 to the base portion 100. The structure of a microneedle having a reservoir will be described in detail below.

[0015] The planar shape of the base portion 100 may be any shape such as a circle, an ellipse, or a polygon, and may be, for example, a rectangle.

[0016] [Needle] The length of the needle 110 is not limited as long as it is long enough to reach the stratum corneum when punctured into the skin. For example, it may be preferably 5 mm or less, more preferably 2 mm or less, and even more preferably 1 mm or less. It is also preferably 100 μm or more, more preferably 500 μm or more, and even more preferably 1 mm or more in one embodiment. The number and arrangement of the needles 110 may be arbitrary. For example, multiple needles 110 may be arranged in an M×N matrix (M and N are each integers from 1 to 30). As a specific example of the arrangement, 10×12 needles 110 are arranged at a 500 μm pitch in an 8 mm×8 mm rectangular area. As another example of the arrangement, 11×11 needles 110 are arranged at a 1.2 mm pitch in a 12 mm diameter circular area. The shape of the needle 110 may be arbitrary as long as it has a tip capable of puncturing the skin, and preferably is pyramidal.

[0017] The needle 110 contains a gel composition capable of carrying and releasing a drug. In particular, when the microneedle 10 is a microneedle that delivers insulin as a drug, a sugar-responsive gel can be used as the gel composition. The sugar-responsive gel will be described later.

[0018] [Structure of Microneedle Having Reservoir] As one aspect of this embodiment, one form of the structure of a microneedle having a reservoir will be described with reference to FIG.

[0019] In the embodiment shown in FIG. 2 , the base portion 100 is formed in a concave (cup-like) shape, and the open upper surface of the base portion 100 is sealed with a sheet 102, forming a space that forms the reservoir 101. For example, a water-resistant adhesive 103 can be used to adhere the sheet 102. There are no particular limitations on the sheet 102, but from the standpoint of water resistance and flexibility, for example, a silicone sheet with a thickness of 0.3 mm can be used. The drug can be filled into the reservoir 101 through the sheet 102 by syringe injection.

[0020] <Sugar-Responsive Gel> Next, the sugar-responsive gel will be described. The sugar-responsive gel (also referred to as a "gel composition" or "gel") of this embodiment utilizes the mechanism by which a phenylboronic acid monomer changes its structure depending on the glucose concentration, as described below.

[0021]

[0022] Phenylboronic acid (PBA) dissociates in water and reversibly binds to sugar molecules, maintaining the above-mentioned equilibrium state. When the glucose concentration increases, glucose binds to the boronic acid, causing the gel volume to expand, whereas when the glucose concentration is low, the gel contracts. When the gel is filled into a drug delivery device, this reaction occurs at the gel interface in contact with blood, causing the gel to contract only at the interface, forming a dehydration-shrunk layer that the inventors call the "skin layer." An insulin delivery device according to one embodiment of the present invention utilizes this property to control insulin release.

[0023] The sugar-responsive gel of this embodiment comprises a polymerization reaction product of a mixture containing (A) a gelling agent, (B) a phenylboronic acid-based monomer, (C) a hydroxyl-based monomer, (D) a crosslinking agent, and (E) a photopolymerization initiator, and is a copolymer containing monomer units based on components (A) to (D). In this specification, the term "monomer unit" refers to a structural unit in a (co)polymer derived from a monomer, and the term "monomer" is sometimes used to mean "monomer unit."

[0024] These components (A) to (E) will be described in detail below.

[0025] <(A) Gelling Agent> The mixture used to prepare the sugar-responsive gel of this embodiment contains (A) a gelling agent (also referred to as "component (A)") containing at least one selected from the group consisting of N-isopropylmethacrylamide (NIPMAAm), N-isopropylacrylamide (NIPAAm), N,N-dimethylacrylamide (DMAAm), and N,N-diethylacrylamide (DEAAm). The gelling agent forms the main chain of the sugar-responsive gel.

[0026] The gelling agent may be any biocompatible material that is biocompatible and capable of gelling, such as a biocompatible acrylamide compound (a compound having one acrylamide group or one methacrylamide group). The gelling agent preferably contains at least one compound selected from the group consisting of N-isopropylmethacrylamide (NIPMAAm), N-isopropylacrylamide (NIPAAm), N,N-dimethylacrylamide (DMAAm), and N,N-diethylacrylamide (DEAAm), and may contain two or more compounds.

[0027] The gelling agent (component (A)) can be contained in a proportion of, for example, 50 mol% or more, 60 mol% or more, 70 mol% or more, or 80 mol% or more, relative to the total of components (A) to (E). The gelling agent can be contained in a proportion of, for example, 90 mol% or less, 80 mol% or less, 70 mol% or less, or 60 mol% or less, relative to the total of components (A) to (E). In one embodiment, the concentration of the gelling agent relative to the total of components (A) to (E) is preferably 50 mol% or more, more preferably 60 mol% or more, even more preferably 65 mol% or more, and is preferably 90 mol% or less, more preferably 80 mol% or less.

[0028] <(B) Phenylboronic Acid Monomer> The mixture used to prepare the sugar-responsive gel of this embodiment is a phenylboronic acid monomer represented by the following general formula (1):

[0029] wherein R is H or CH 3 wherein F is present independently, n is 1, 2, 3, or 4, and m is 0 or an integer of 1 or greater.] (also referred to as "component (B)," or simply as "phenylboronic acid monomer" or "phenylboronic acid").

[0030] The above-mentioned phenylboronic acid monomer has a fluorinated phenylboronic acid group in which the hydrogen atoms on the phenyl ring are substituted with one to four fluorines, and has a structure in which the carbon atoms of an amide group are bonded to the phenyl ring. Phenylboronic acid monomers having the above structure are highly hydrophilic, and the fluorination of the phenyl ring allows the pKa to be set to a biological level of 7.4 or less. Furthermore, this phenylboronic acid monomer not only acquires sugar recognition ability in a biological environment, but also allows copolymerization with the gelling agent (component (A)), the hydroxyl monomer (component (C)), and the crosslinking agent (component (D)) due to the unsaturated bond, and can form a gel that undergoes a phase change depending on the glucose concentration.

[0031] In the phenylboronic acid monomer, when one hydrogen atom on the phenyl ring is replaced by fluorine, F and B(OH) 2 The introduction position may be ortho, meta, or para.

[0032] Generally, a phenylboronic acid monomer in which m is 1 or more can have a lower pKa than a phenylboronic acid monomer in which m is 0. The upper limit of m is not particularly limited, but is, for example, 20 or less, preferably 10 or less, and more preferably 4 or less.

[0033] An example of the phenylboronic acid monomer is a phenylboronic acid monomer in which R is hydrogen, n is 1, and m is 2, and this is 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (AmECFPBA), which is particularly preferred as a phenylboronic acid monomer.

[0034] The phenylboronic acid monomer (component (B)) represented by general formula (1) may be contained in a proportion of, for example, 5 mol% or more, 10 mol% or more, or 15 mol% or more, relative to the total of components (A) to (E). Furthermore, the phenylboronic acid monomer represented by general formula (1) may be contained in a proportion of, for example, 35 mol% or less, 30 mol% or less, 25 mol% or less, or 20 mol% or less, relative to the total of components (A) to (E). In one embodiment, the concentration of the phenylboronic acid monomer relative to the total of components (A) to (E) is, for example, preferably 5 mol% or more, more preferably 10 mol% or more, and preferably 30 mol% or less, more preferably 25 mol% or less.

[0035] <(C) Hydroxyl-based monomer> The mixture used to prepare the sugar-responsive gel of this embodiment contains (C) a hydroxyl-based monomer represented by the following general formula (2):

[0036] [In the formula, R 1 is H or CH 3 m is an integer of 0 or 1 or more, and R 2 is a saturated or unsaturated C substituted with OH, one or more hydroxyl groups 1-6 alkyl group, saturated or unsaturated C substituted with one or more hydroxyl groups 3-10 a cycloalkyl group, a C group containing 1 to 4 heteroatoms selected from NH, O, and S substituted with one or more hydroxyl groups; 3-12 Heterocyclic groups, C substituted with one or more hydroxyl groups 6-12 The hydroxyl group is an aryl group, a monosaccharide group, or a polysaccharide group.] The use of the hydroxyl monomer makes it possible to form a gel that is highly resistant to temperature changes and can inhibit the release of a large amount of a drug, particularly at low temperatures.

[0037] The monomer of general formula (2) has a hydroxyl group in the molecule. Without being bound by any particular theory, it is believed that this hydroxyl group increases the hydrophilicity of the gel, offsets the hydrophobicity of the boronic acid, and acts on the boronic acid in the gel to prevent excessive swelling of the gel. The upper limit of m is not particularly limited, but is, for example, 20 or less, preferably 10 or less, and more preferably 4 or less.

[0038] An example of the hydroxyl-based monomer is R 1 is hydrogen, m is 1, and R 2 is OH, and this is N-hydroxyethyl acrylamide (NHEAAm), which is particularly preferred as a hydroxyl monomer. In particular, by using ethyl instead of methyl as the side chain, the degree of rotational freedom of the side chain is increased, which has the effect of significantly improving the efficiency of the intermolecular cross-linking reaction (with the boronic acid side chain). Therefore, by using NHEAAm, it is possible to obtain an optimal gel that undergoes a phase change depending on the glucose concentration. Note that, in other examples of hydroxyl monomers, 2 may be, for example, a sugar derivative such as a catechol group or a glycolyl group. The monosaccharide may be, for example, glucose.

[0039] The hydroxyl monomer represented by general formula (2) (component (C)) can be contained in a proportion of, for example, 8 mol% or more, 10 mol% or more, 12 mol% or more, 13 mol% or more, or 15 mol% or more relative to the total of components (A) to (E). Furthermore, the concentration of the hydroxyl monomer represented by general formula (2) (component (C)) relative to the total of components (A) to (E) can be, for example, 21 mol% or less, 20 mol% or less, 18 mol% or less, 17 mol% or less, 16 mol% or less, 15 mol% or less, or 14 mol% or less. The concentration range can be specified by any combination of the above upper and lower limits. A preferred concentration range of component (C) relative to the total of components (A) to (E) is, for example, preferably 11 mol% or more, more preferably 12 mol% or more, even more preferably 13 mol% or more, and is preferably 20 mol% or less, more preferably 18 mol% or less, even more preferably 16 mol% or less, and still more preferably 15 mol% or less.

[0040] <(D) Crosslinking Agent> The mixture used to prepare the sugar-responsive gel of this embodiment contains (D) a crosslinking agent (also referred to as "component (D)"). The crosslinking agent may be any substance that is biocompatible and capable of crosslinking monomers, and preferably includes a compound having at least two acrylamide or methacrylamide groups in the molecule. Examples of crosslinking agents include N,N'-methylenebisacrylamide (MBAAm), ethylene glycol dimethacrylate (EGDMA), and N,N'-methylenebismethacrylamide (MBMAAm).

[0041] The crosslinking agent (component (D)) can be contained in an amount of, for example, 1 mol% or more, 1.5 mol% or more, 2 mol% or more, 2.3 mol% or more, or 2.5 mol% or more relative to the total of components (A) to (E). Furthermore, component (D) can be contained in an amount of 5 mol% or less, 4.5 mol% or less, 4 mol% or less, 3.5 mol% or less, 3 mol% or less, or 2.5 mol% or less relative to the total of components (A) to (E). The concentration range is a combination of the above upper and lower limits.

[0042] <(E) Photopolymerization initiator> The mixture used to prepare the sugar-responsive gel of this embodiment contains (E) a photopolymerization initiator (also referred to as "component (E)"). The photopolymerization initiator generates radicals, acids, bases, etc. when irradiated with actinic rays such as ultraviolet rays, and can be appropriately selected depending on the type of monomer, etc., and it is preferable to use a photoradical polymerization initiator.

[0043] The photoradical polymerization initiator is preferably one that is sensitive to ultraviolet light with a wavelength shorter than 405 nm, and from the viewpoint of being able to fully utilize the energy emitted from the light source and achieving excellent productivity, it is preferable that the maximum absorption wavelength be 300 nm to 400 nm, and more preferably 300 nm to 380 nm. The photoradical polymerization initiator is not particularly limited, but examples include alkylphenone-based radical polymerization initiators, acylphosphine oxide-based radical polymerization initiators, and oxime ester-based radical polymerization initiators. These photopolymerization initiators may be used alone or in combination of two or more.

[0044] Examples of alkylphenone-based photopolymerization initiators include 2,2-dimethoxy-1,2-diphenylethan-1-one (IGM Resins, Omnirad 651), 1-hydroxy-cyclohexyl-phenyl-ketone (IGM Resins, Omnirad 184), 2-hydroxy-2-methyl-1-phenyl-propan-1-one (IGM Resins, Omnirad 1173), 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propan-1-one, 2-hydroxy-1-{4-[4-(2-hydroxy-2-methyl-propionyl)-benzyl]phenyl}-2-methyl-propan-1-one (IGM Resins, Omnirad 127), 2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one (IGM Resins, Omnirad 907), 2-benzyl-2-dimethylamino-1-(4-morpholinophenyl)-butanone-1,2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(4-morpholinyl)phenyl]-1-butanone (IGM Resins, Omnirad 379EG), and the like.

[0045] Examples of the acylphosphine oxide photopolymerization initiator include 2,4,6-trimethylbenzoyl-diphenyl-phosphine oxide (IGM Resins, Omnirad TPO H) and bis(2,4,6-trimethylbenzoyl)-phenylphosphine oxide (IGM Resins, Omnirad 819).

[0046] Examples of the oxime ester radical polymerization initiator include 1-[4-(phenylthio)phenyl]-1,2-octanedione-2-(O-benzoyloxime) (trade name: OmniradOXE-01, manufactured by IGM Resins).

[0047] The content of the photopolymerization initiator (component (E)) is not particularly limited, but is, for example, preferably 1 mol % or more, more preferably 2 mol % or more, and preferably 11 mol % or less, more preferably 5 mol % or less, based on the total of components (A) to (E). When the polymerization reaction is carried out in a solvent, the concentration of the photopolymerization initiator is, for example, preferably 1.3 (w / v) % or more, more preferably 1.6 (w / v) % or more, even more preferably 3.2 (w / v) % or more, and preferably 15.0 (w / v) % or less, more preferably 10 (w / v) % or less, and even more preferably 7 (w / v) % or less. If the content of the photopolymerization initiator is too low, polymerization may be insufficient. On the other hand, if the content of the photopolymerization initiator is too high, the gel may become non-uniform and brittle.

[0048] A preferred embodiment of the sugar-responsive gel is, for example, a polymer of a mixture obtained by mixing, in a predetermined molar ratio, N-isopropylmethacrylamide (NIPMAAm) as a gelling agent (main chain), 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (AmECFPBA) as a phenylboronic acid monomer, N-hydroxyethylacrylamide (HEAAm) as a hydroxyl monomer, N,N'-methylenebisacrylamide (MBAAm) as a crosslinking agent, and 2,2-dimethoxy-1,2-diphenylethan-1-one as a photopolymerization initiator. A more preferred embodiment of the sugar-responsive gel of this embodiment is, for example, a polymer of a mixture of (NIPMAAm / AmECFPBA / HEAAm / MBAAm / 2,2-dimethoxy-1,2-diphenylethan-1-one) prepared in a molar ratio of 65 to 70 / 10 to 15 / 10 to 15 / 1 to 5 / 1 to 5. As an example, it is preferable to adjust the ratio to 68.66 / 12.11 / 13.46 / 2.8 / 2.94.

[0049] The inventors of the present invention conducted detailed studies on the composition of sugar-responsive gels prepared by photopolymerization. They found that by controlling the molar ratio of (the sum of components (A) and (B)):component (C)) within a predetermined range and the concentration of the crosslinker (component (D)) within a predetermined range (i.e., controlling the crosslink density within a predetermined range), a gel can be obtained that accurately responds to changes in sugar concentration even when there is a temperature change and is excellent at suppressing drug release (leakage) when the sugar concentration is below normal. While the body temperature of mammals, including humans, is generally maintained at a nearly constant level, a patient's body temperature may temporarily drop, for example, after anesthesia is administered to the patient or immediately after the drug delivery device is implanted in the patient's body when starting treatment with a drug delivery device. Even in such cases, the sugar-responsive gel of this embodiment accurately responds to changes in sugar concentration and is excellent at suppressing drug release (leakage) when the sugar concentration is below normal.

[0050] In the mixture for preparing the sugar-responsive gel of this embodiment, the molar ratio (total of the gelling agent of component (A) and the phenylboronic acid monomer of component (B)) to the hydroxyl monomer of component (C) (also referred to as the "molar ratio of (A+B):C") is preferably 4.5:1 to 6.5:1, more preferably 4.8:1 to 6.3:1, even more preferably 5.0:1 to 6.3:1, and even more preferably 5.5:1 to 6.3:1. If the total amount of components (A) and (B) is too small relative to the amount of component (C), the drug may be released even when the glucose concentration is below the normal value, or the gel may not respond accurately to changes in glucose concentration. If the total amount of components (A) and (B) is too large relative to the amount of component (C), the drug may not be released easily when the glucose concentration is high.

[0051] In the mixture for preparing the sugar-responsive gel of this embodiment, the ratio of the crosslinker of component (D) (also referred to as "crosslink density") to the total of 100 mol% of components (A), (B), and (C) is preferably 1.5 mol% or more, more preferably 2.0 mol% or more, even more preferably 2.5 mol% or more, and even more preferably 2.8 mol% or more, and is preferably 4 mol% or less, more preferably 3.5 mol% or less. If the crosslink density is too low, the gel may have poor moldability and strength, while if the crosslink density is too high, the drug release amount may be insufficient. Furthermore, by keeping the crosslink density within the above range, the gel can respond more accurately to changes in sugar concentration.

[0052] The sugar-responsive gel may contain other components such as silk fibroin and polyglycerol, if necessary, or may form a complex with other components.

[0053] In one embodiment, the total content of components (A) to (E) in the total amount (100% by mass) of the mixture used to prepare the sugar-responsive gel is preferably 90% by mass or more, more preferably 95% by mass or more, and may be 100% by mass.

[0054] <Method for Preparing Sugar-Responsive Gel> The gel can be prepared by mixing the above components (A) to (E) and copolymerizing the monomers by photopolymerization. The order and means for mixing the components are not particularly limited. Mixing the components is preferably carried out in a solvent. Any solvent capable of dissolving the monomers can be used. Examples of such solvents include water, alcohol, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), ionic liquids, and combinations of two or more thereof. Among these, aqueous methanol and 2-methoxyethanol are preferred, with 2-methoxyethanol being particularly preferred. When preparing the gel using a solvent, although not particularly limited, the total monomer concentration of components (A), (B), (C), and (D) in the solution is preferably 1 to 10 M, more preferably 3 to 8 M. In this specification, the unit "M" means "mol / L." Known mixing devices, such as ultrasonic dispersion devices, can be used. The temperature during mixing is not particularly limited and may be, for example, room temperature (preferably 5 to 40°C, more preferably 10 to 35°C). In one embodiment, components (A) to (D) are mixed to prepare a monomer solution, and component (E) is added to this just before the polymerization reaction to form a pre-gel solution. In another embodiment, two or more monomer solutions with different compositions are prepared, and then mixed to obtain a desired composition, and component (E) is added to the resulting mixture.

[0055] The sugar-responsive gel of this embodiment is obtained by irradiating a pre-gel solution containing components (A) to (E) with light to polymerize the monomers. Specific examples of the light to be irradiated include one or more types of light selected from the group consisting of visible light, ultraviolet light, infrared light, X-rays, α-rays, β-rays, and γ-rays, and actinic electron beams. Among these, ultraviolet light is preferred because it is easy to control the progress of the polymerization reaction and because widely used photopolymerization devices can be used. Examples of light sources include low-pressure mercury lamps, medium-pressure mercury lamps, high-pressure mercury lamps, ultra-high-pressure mercury lamps, xenon lamps, halogen lamps, carbon arc lamps, tungsten lamps, gallium lamps, excimer lasers, LED light sources, chemical lamps, black light lamps, microwave-excited mercury lamps, and metal halide lamps.

[0056] When the photopolymerization reaction is carried out using ultraviolet light, the ultraviolet irradiation intensity is not particularly limited, but is preferably 10 to 3,000 mW / cm. 2 , more preferably 10 to 1000 mW / cm 2 , and more preferably 10 to 500 mW / cm 2 The ultraviolet irradiation intensity is preferably an intensity in a wavelength region effective for activating the photopolymerization initiator. The light irradiation time is preferably 0.1 seconds to 10 minutes, more preferably 0.1 seconds to 5 minutes, and even more preferably 0.1 seconds to 3 minutes. When irradiating once or multiple times with such ultraviolet irradiation intensity, the cumulative light amount is preferably 10 to 3,000 mJ / cm. 2 , more preferably 50 to 2,000 mJ / cm 2 , and more preferably 100 to 1,000 mJ / cm 2 is.

[0057] [Manufacturing of Microneedles] The microneedles 10 can be manufactured using a micromolding technique using a mold. With micromolding, the needle 110 can be formed integrally with the base portion 100, so it is preferable to use a mold 200 having a cavity (recess) 201 formed in the shape of the needle and the base portion combined, as shown in FIG. 3. As a material for forming the mold 200, for example, a silicone material such as polydimethylsiloxane (PDMS) can be used. In this embodiment, the material for forming the mold 200 is preferably a material that can transmit light for photopolymerizing the monomer in the pre-gel solution.

[0058] By using such a mold 200, the base portion 100 and the needle 110 can be formed in a single process. However, if the material constituting the base portion 100 and the material constituting the needle 110 are different, first, a solution (pre-gel solution) in which the material constituting the needle 110 is dissolved in a solvent is poured into the portion of the mold 200 corresponding to the needle 110, and the monomer of the pre-gel solution is polymerized within the mold 200 by light irradiation, and then dried (solvent is removed) to form the needle 110. The pouring and drying of the solution can also be performed multiple times. Next, a solution in which the material constituting the base portion 100 is dissolved in a solvent is poured into the mold 200 and dried. The resulting molded body is removed from the mold 200. This allows for the production of a microneedle 10 in which the base portion 100 and the needle 110 are integrally molded.

[0059] In another embodiment, a solution (pre-gel solution) obtained by dissolving a monomer mixture containing the monomers constituting the needles 110 in a solvent is poured (injected) into the cavity 201 corresponding to the needles 110 of the microneedle mold 200. The amount of solution poured into the microneedle mold 200 is an amount that fills at least the portion of the cavity 201 corresponding to the needles 110 with the solution. Next, a sheet corresponding to the base portion 100 is inserted into the microneedle mold 200 from above the poured solution. Examples of the sheet corresponding to the base portion 100 include a PE (polyethylene) sheet, and it may also be a porous PE sheet. A porous body is inserted into the microneedle mold 200 so that the liquid surface of the solution contacts the porous body at the portion where the solution and the PE sheet face each other. Alternatively, a PE sheet having a gel layer with the same composition as the needles 110 may be prepared, and the PE sheet may be arranged so that the gel layer portion on the PE sheet contacts the solution in the portion corresponding to the needles 110.

[0060] Since the needle 110 has a very fine structure, it is important to fill the solution up to the tip of the needle 110 when forming the needle 110. Therefore, after filling the solution, centrifugation, vacuum treatment, or degassing treatment may be performed.

[0061] As described above, the sugar-responsive gel that constitutes the microneedle of this embodiment is formed by a photopolymerization reaction of components (A) to (E). In one embodiment, the solution (including the monomer mixture) poured into the needle 110, or into the mold for the base portion 100 and the needle 110, is degassed, and then the monomer mixture is polymerized by light irradiation. The light irradiation method is as described in the gel preparation method above. The direction of light irradiation is not particularly limited, but it is preferable to irradiate from the tip of the needle, for example.

[0062] The molded body (microneedle 10) removed from the mold 200 contains unreacted monomers and unpolymerized polymers in its original state. Therefore, after removing the molded body from the mold 200, the removed molded body is washed. A mixed solution of methanol and water is used as a washing solution for washing. The washing solution preferably has a methanol concentration of 40% to 70% by volume. The higher the methanol concentration, the more the gel composition swells, and washing proceeds more efficiently. However, if the methanol concentration is too high, the gel composition may deform significantly due to swelling, making it more likely that the desired needle shape will not be obtained, and there is a higher risk of the gel composition cracking during drying. On the other hand, if the methanol concentration is too low, washing efficiency decreases.

[0063] Furthermore, cleaning can be performed, for example, by placing the molded body in an appropriate container filled with cleaning liquid. While it is not necessary to replace the cleaning liquid during cleaning, it is preferable to do so. By replacing the cleaning liquid, the molded body comes into contact with fresh cleaning liquid more frequently, thereby improving cleaning efficiency and shortening cleaning time. The cleaning liquid may be replaced once or multiple times (e.g., two, three, four, five, six, seven, eight, or nine times). The immersion time of the molded body in the cleaning liquid (the time per replacement of the cleaning liquid when the cleaning liquid is replaced) can be set arbitrarily within the range of 2 to 24 hours, for example, 2, 3, 5, 8, 10, 12, 18, or 24 hours. An excessively long immersion time will result in a decrease in cleaning effectiveness. The frequency of replacement of the cleaning liquid and the immersion time of the molded body in the cleaning liquid can be determined according to the methanol concentration of the cleaning liquid. When the methanol concentration is high, a shorter replacement frequency and immersion time are sufficient.

[0064] <Drug Delivery Device> The present invention is not limited to the microneedle 10, but can also be applied to a drug delivery device (also referred to as a "drug delivery device" or simply "device") containing a glucose-responsive gel. The drug delivery device is preferably used for delivering insulin. The drug delivery device can take any form, such as an implantable type, a microneedle type, or a tablet type. For implantable devices, see, for example, Japanese Patent Application Laid-Open No. 2016-209372 and International Publication Pamphlet WO2017 / 069282. The drug delivery device may also be implanted in the body as a gel tablet (see Examples below). The shape and size of the gel tablet are not particularly limited.

[0065] In drug delivery devices, a drug (e.g., insulin) may be pre-loaded into the gel. To achieve this, the gel can be immersed in an aqueous solution (e.g., phosphate buffer solution) containing a predetermined concentration of the drug, allowing the drug to diffuse into the gel. The gel is then removed from the aqueous solution and immersed in, for example, hydrochloric acid for a predetermined period of time, forming a thin dehydration-shrunk layer (called a skin layer) on the surface of the gel body, thereby encapsulating (loading) the drug and obtaining a gel that can be loaded into the device.

[0066] In glucose-responsive gels, a phenylboronic acid monomer and a hydroxyl monomer are copolymerized with a gelling agent and a crosslinker to form the gel body. Drugs such as insulin can be diffused into this gel, and the surface of the gel body can be surrounded by a dehydration-shrinkable layer. Under physiological conditions (e.g., pKa 7.4 or less, temperature 35°C to 40°C), when the glucose concentration increases, the gel expands and the dehydration-shrinkable layer disappears, allowing the drug (e.g., insulin) within the gel to be released to the outside. On the other hand, when the glucose concentration decreases again, the expanded gel contracts, forming a dehydration-shrinkable layer (skin layer) over the entire surface again, preventing the drug (e.g., insulin) from being released to the outside. Therefore, the glucose-responsive gel used in the present invention can autonomously release drugs (e.g., insulin) in response to glucose concentration.

[0067] <Drugs> Drugs that can be delivered using the sugar-responsive gel of this embodiment include, but are not limited to, proteins, peptides, nucleic acids, other high molecular weight polymers, and low molecular weight compounds. Drugs may also be therapeutic agents for diseases, preventive drugs, vaccines, nutritional supplements, and the like. A particularly preferred drug is insulin. Various natural insulins or modified insulins are available commercially or by synthesis. For example, Humulin (registered trademark) may be used as insulin. Humulin (registered trademark) is a human (recombinant) insulin sold by Eli Lilly and Company. Various insulin preparations, including rapid-acting, intermediate-acting, and sustained-acting types, have been developed, and an appropriate one can be selected and used.

[0068] The present invention will be specifically explained by the following examples, but the present invention is not limited to these examples.

[0069] <Preparation of pre-gel solution> The materials (monomers) used to prepare the monomer solution are as follows: (Gelling agent (main chain)) NIPAAm: N-isopropylacrylamide (Phenylboronic acid) AmECFPBA: 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic acid (Hydroxyl monomer) NHEAAm: N-hydroxyethylacrylamide (Crosslinking agent) MBAAm: N,N'-methylenebisacrylamide

[0070] In this example, the total concentration of monomers other than the crosslinker (gelling agent, phenylboronic acid, and hydroxyl-based monomer) is 5 M, and the crosslink density is 3%, which is described as "5M 3%." The same applies to other compositions. "Crosslink density" refers to the molar concentration of the crosslinker relative to the total amount of the gelling agent, phenylboronic acid, and hydroxyl-based monomer.

[0071] <Preparation of Monomer Solutions> 5M 3% Monomer Solution A (also referred to as "Monomer Solution A") and 5M 3% Monomer Solution B (also referred to as "Monomer Solution B") were prepared as monomer solutions for producing a 5M 3% gel. Reagents (monomers) were added to 2-methoxyethanol as a solvent and dissolved by ultrasonic irradiation at room temperature for 5 minutes to obtain the following concentrations, thereby preparing Monomer Solution A and Monomer Solution B. The resulting Monomer Solutions A and B were stored refrigerated.

[0072] <Crosslink density: 3%, 5M 3% Monomer Solution A> (Crosslinking agent) MBAAm: 5M × 0.03 × 154.17 = 23.12 mg / mL (Gelling agent) NIPAAm: 5M × 0.85 × 113.16 = 480.93 mg / mL (Phenylboronic acid monomer) AmECFPBA: 5M × 0.15 × 280 = 210 mg / mL

[0073] <Crosslink density: 3%, 5M 3% Monomer Solution B> (Crosslinking agent) MBAAm: 5M × 0.03 × 154.17 = 23.12 mg / mL (Hydroxyl monomer) NHEAAm: 5M × 115.13 = 575.65 mg / mL

[0074] When preparing the microneedles, the monomer solution A and the monomer solution B were mixed with a vortex mixer to a mixing ratio (volume ratio) of 6:1 (monomer solution A:monomer solution B), and 40 mg of a photopolymerization initiator (Irgacure 651 (Omnirad 651), manufactured by BASF Japan) was added to 1 mL of the mixed solution, and the mixture was completely dissolved by ultrasonic irradiation for 10 minutes to produce a pre-gel solution. The mixing ratio of the monomer solution A and the monomer solution B corresponds to the molar ratio of {(NIPAAm + AmECFPBA): NHEAAm}, that is, {(gelling agent + phenylboronic acid monomer): hydroxyl monomer}. The concentration of the crosslinker (crosslink density) represents the ratio (mol) of MBAAm to the total of AmECFPBA, NIPAAm, and NHEAAm in the mixed monomer solution.

[0075] <Preparation of Microneedles> (Preparation of PE Plate with Gel Layer) A PE (polyethylene) plate with a thickness of 2 mm and a diameter of 11 mm was gently placed on 165 μL of pre-gel solution poured into a concave mold with a depth of 0.5 mm, a circular bottom with a diameter of 11 mm, and an open top, and was immediately exposed to UV irradiation (wavelength 365 nm, 150 mW / cm 2 After that, the PE plate with the gel layer was prepared. The PE plate with the gel layer corresponds to the base of the microneedle.

[0076] (Molding of microneedles) 125 μL of pre-gel solution kept at 50 ° C. was placed in the cavity corresponding to the needle of a silicone (made of polydimethylsiloxane (PDMS)) microneedle mold preheated to 50 ° C., and the pressure was reduced using a water pump to remove air bubbles. This operation was repeated twice. Next, the PE plate with the gel layer prepared above (PE plate prepared using the pre-gel solution) was gently inserted, and UV irradiation (wavelength 365 nm, 150 mW / cm) was applied from the needle tip side. 2 After several minutes of irradiation, when the mold had cooled to room temperature, the microneedle gel was gently removed from the mold and air-dried overnight at room temperature to obtain a molded product in which the PE plate and needles were integrated.

[0077] (Cleaning of Microneedles) The molded body (microneedles) removed from the mold 200 was washed. The washing was performed as follows. First, the molded body was placed in a container containing a cleaning solution while immersed in the cleaning solution, and allowed to stand at room temperature for 50 hours. A mixed solution of methanol and water (methanol concentration = 60% by volume) was used as the cleaning solution. During this standing period, the cleaning solution was replaced 2 hours and 26 hours after the start of immersion of the molded body.

[0078] The molded body was then further immersed in the cleaning solution at room temperature until the pH of the cleaning solution reached 6 or higher. pH was measured using the glass electrode method. A pH meter F-5 (2) and a pH electrode 9618S-10D manufactured by Horiba, Ltd. were used for the measurements. The same mixed solution of methanol and water (methanol concentration = 60% by volume) was used as the cleaning solution. The cleaning solution was appropriately changed during this immersion period.

[0079] When the pH of the cleaning solution reached 6 or higher, the mixed solution of methanol and water was replaced with pure water, and the molded body was immersed in the pure water at room temperature for 24 hours or more. Thereafter, the molded body was removed from the pure water and air-dried to obtain microneedles.

[0080] (Confirmation of Cleaning Effect) From the viewpoint of confirming safety to living organisms, the cleaning effect was confirmed by the following procedure.

[0081] In the above-described cleaning process, the mixed solution was recovered each time the cleaning solution (methanol and water mixed solution) was replaced. The recovered mixed solution was concentrated using an evaporator and dissolved in deuterated methanol. The substances contained in the mixed solution were then analyzed using a nuclear magnetic resonance analyzer (AVANCE III 400, manufactured by Bruker).

[0082] As a result of the analysis, it was confirmed that the concentrations of unreacted monomers and unpolymerized polymers decreased significantly after two days from the start of cleaning, as shown in FIG.

[0083] Regarding safety in living organisms, the U.S. Food and Drug Administration (FDA) standard for acrylamide tolerance is 0.36 μg / kg body weight / day, which translates to 25.2 μg / day for a 70 kg body weight. This confirmed that the safety limit was reached within three days of the start of washing. Furthermore, acrylamide has been cited as a potential risk factor for neurotoxicity and carcinogenicity. The recommended limit for preventing neurotoxicity is 40 μg / kg body weight / day or less, and the recommended limit for carcinogenicity is 2.6 μg / kg body weight / day or less. These limits were also confirmed to be within acceptable limits.

[0084] While preferred embodiments of the present invention are described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only, and that various modifications, changes, and substitutions may be made by those skilled in the art without departing from the invention. It should be understood that various alternative embodiments of the invention described herein may be used in practicing the invention. Furthermore, the contents of all publications, including patents and patent applications, referenced herein should be construed as incorporated by reference as if expressly set forth herein.

[0085] 10 Microneedle 100 Base part 101 Reservoir 110 Needle 200 Mold 201 Cavity

Claims

1. A method for manufacturing a microneedle, comprising the steps of: preparing a mold having a base portion and at least one needle portion integrally formed with the base portion, the mold having a cavity corresponding to the base portion and the needle portion; preparing a pre-gel solution containing a monomer mixture; injecting the pre-gel solution into at least the cavity portion of the mold corresponding to the needle; polymerizing the monomer mixture in the pre-gel solution in the mold to form a gel composition; removing the obtained molded body from the mold; washing the molded body removed from the mold; and drying the molded body after washing, wherein the step of washing the molded body includes immersing the molded body in a mixed solution of methanol and water.

2. The method for producing a microneedle according to claim 1, wherein the methanol concentration of the mixed solution is 30% by volume to 70% by volume.

3. The method for producing a microneedle according to claim 1, wherein the step of washing the molded body includes replacing the mixed solution one or more times.

4. The method for manufacturing a microneedle according to claim 3, wherein the immersion time of the molded body in each exchange of the mixed solution is 2 to 24 hours.

5. The method for producing a microneedle according to claim 1, wherein the monomer mixture comprises a gelling agent, a phenylboronic acid-based monomer, a hydroxyl-based monomer and a crosslinking agent.

6. The method for producing a microneedle according to claim 5, wherein the monomer mixture further contains a photopolymerization initiator, and the step of forming the gel composition includes polymerizing the monomer mixture by irradiating it with light.

Citation Information

Patent Citations

  • Micro-needle array and patch

    JP2022083780A

  • Drug delivery device and method for producing the same

    JP2023037496A

  • Drug delivery device and method for producing same

    WO2023033144A1